BIOCRYST PHARMACEUTICALS INC

BCRX Nasdaq CIK: 0000882796

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703
Mailing Address 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703
Phone 919-859-1302
Fiscal Year End 1231
EIN 621413174

Financial Overview

FY2025

$514.16M
Total Assets
-$119.15M
Stockholders' Equity
$1.26
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
8-K Current report of material events February 26, 2026 View on SEC
10-K Annual financial report February 26, 2026 View on SEC

Annual Reports

10-K February 26, 2026
  • Robust ORLADEYO sales drove a 15.4% total revenue increase to $360 million in 2025.
  • Significant improvement in operating loss to $50 million and net loss to $80 million, signaling progress towards profitability.
View Analysis

Insider Trading

STRONG SELL 2 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.